Download presentation
Presentation is loading. Please wait.
Published byPaulette Durand Modified over 5 years ago
1
Fig. 4 Topical application of SAAP-148 ointment eradicates acute and established infections of MRSA and A. baumannii from the skin. Topical application of SAAP-148 ointment eradicates acute and established infections of MRSA and A. baumannii from the skin. (A to F) Ex vivo wounded human skin (A to C) and in vivo abraded murine skin (D to F) were inoculated with MRSA LUH14616 (gray circles) or A. baumannii RUH875 (black circles). Ten minutes after inoculation (D) or 1 hour (A), 24 hours (C and E), or 48 hours (F) after inoculation, the skin was treated with ointments containing no peptide (vehicle) or 0.125, 0.5, or 2% (w/w) SAAP-148 ointment. Results are expressed as the numbers of viable bacteria (in log10 CFU) per skin model of three to six donors and of 16 skin samples for each group of mice (eight mice per group and two skin samples per mouse). Each circle represents one skin sample, and bars indicate medians. *, significantly different (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < ) as compared to the vehicle, as calculated using the Mann-Whitney rank sum test. (B) Light micrographs of hematoxylin and eosin–stained skin biopsies 24 hours after inoculation with MRSA and A. baumannii and subsequent vehicle treatment. Arrows indicate biofilm formation, which is shown at a higher magnification in the inset. Anna de Breij et al., Sci Transl Med 2018;10:eaan4044 Published by AAAS
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.